Notably, inhibition of IL-17A (∼75%) by the verteporfin treatment (1 μM) in patients with SLE or RA was more efficient than that (∼48%) in healthy controls (Supplemental Fig. S6B). Here, IL17A is linked to systemic lupus erythematosus.